Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population.

Idiopathic thrombocytopenic purpura (ITP) is an acquired organ-specific autoimmune hemorrhagic disease with many immune dysfunctions. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a T-lymphocyte surface molecule that can down modulate and terminate immune responses. Recently, several studies have confirmed that some polymorphisms of this gene can influence its expression level, therefore speculating that they might be associated with autoimmune diseases. In order to investigate the role of the CTLA-4 gene in ITP, we investigated -318 and CT60 polymorphisms of the CTLA-4 gene in 186 ITP patients and 162 healthy controls through polymerase chain reaction (PCR)-restriction fragment length polymorphism. No significant differences were revealed in genotypes and allele distributions between the patients with ITP and the controls in both sites. Similar results were observed between the two groups when stratified by first onset age and disease course including acute childhood, chronic childhood, acute adult, and chronic adult. In the conclusion, these two single-nucleotide polymorphisms in CTLA-4 are not associated with susceptibility to ITP in a Chinese population.

[1]  K. Zaletel,et al.  49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. , 2009, Human immunology.

[2]  Zhiguang Zhou,et al.  [Association of CTLA-4 + 49A/G and CT60 gene polymorphism with type 1 diabetes and thyroid autoimmunity]. , 2009, Zhonghua yi xue za zhi.

[3]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[4]  M. Ehrenstein,et al.  Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis , 2008, Proceedings of the National Academy of Sciences.

[5]  Linda S. Wicker,et al.  Allelic variant in CTLA4 alters T cell phosphorylation patterns , 2007, Proceedings of the National Academy of Sciences.

[6]  M. Hou,et al.  Modulation of immune response with cytotoxic T‐lymphocyte‐associated antigen 4 immunoglobulin‐induced anergic T cells in chronic idiopathic thrombocytopenic purpura 2 , 2007 .

[7]  L. Lundquist.  Abatacept: a novel treatment for rheumatoid arthritis , 2007, Expert opinion on pharmacotherapy.

[8]  B. Liu,et al.  Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura , 2006, European journal of haematology.

[9]  J. Madrenas,et al.  A molecular perspective of CTLA-4 function. , 2006, Annual review of immunology.

[10]  Y. Belkaid,et al.  Association of CTLA4 polymorphism with regulatory T cell frequency , 2005, European journal of immunology.

[11]  Bin Zhou,et al.  Multi-dysfunctional pathophysiology in ITP. , 2005, Critical reviews in oncology/hematology.

[12]  Ó. Jónsson,et al.  Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease , 2005, Acta paediatrica.

[13]  G. Freeman,et al.  An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. , 2004, Immunity.

[14]  L-L Fung,et al.  Increased Expression of Soluble Cytotoxic T‐Lymphocyte‐Associated Antigen‐4 Molecule in Patients with Systemic Lupus Erythematosus , 2003, Scandinavian journal of immunology.

[15]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[16]  N. Xing,et al.  Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. , 2003, Blood.

[17]  M. Spiroski,et al.  CTLA‐4 exon 1 polymorphism in patients with autoimmune blood disorders , 2003, American journal of hematology.

[18]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[19]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[20]  R. Giscombe,et al.  A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein , 2002, Genes and Immunity.

[21]  J. Madrenas,et al.  CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1 , 2000, The Journal of Immunology.

[22]  M. Oaks,et al.  Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease , 2000, The Journal of Immunology.

[23]  J. Madrenas,et al.  The Inhibitory Function of CTLA-4 Does Not Require Its Tyrosine Phosphorylation1 , 2000, The Journal of Immunology.

[24]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[25]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[26]  P. Linsley,et al.  Treatment of murine lupus with CTLA4Ig. , 1994, Science.

[27]  M. Mattei,et al.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. , 1991, Journal of immunology.

[28]  M. Hou,et al.  Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. , 2008, Journal of thrombosis and haemostasis : JTH.

[29]  I. Khouri,et al.  Immune Thrombocytopenic Purpura , 2018 .

[30]  H. Harbo,et al.  CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. , 1999, Tissue antigens.